Side-by-side · Research reference
P21vsPTD-DBM
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BAnimal-StrongHUMAN-REVIEWED10/40 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
P21
PTD-DBM
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
CXXC5–Dishevelled protein-protein interaction
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Feedback intact?
—
Not applicable — pathway derepression rather than receptor agonism
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
Antibody development
—
—
02Dosage Protocols
Parameter
P21
PTD-DBM
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Animal models only (mice)
Duration
Not specified
—
Route
Presumed subcutaneous or intraperitoneal (animal studies)
—
Wound healing protocol
—
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
Hair regeneration protocol
—
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
Co-administration
—
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
Human translation
—
No published human studies
04Side Effects & Safety
Parameter
P21
PTD-DBM
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Reported adverse events
—
None reported in animal studies
Wnt pathway activation risks
—
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
Long-term safety
—
Unknown — no chronic dosing or human data
Delivery vehicle effects
—
HA-PG hydrogel well-tolerated in mice; human translation pending
Absolute Contraindications
P21
- ·Use in humans not validated
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
05Administration Protocol
Parameter
P21
PTD-DBM
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
3. Combination Therapy
—
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
4. Storage & Handling
—
Not disclosed in available literature. Peptide stability and storage conditions not published.